Drug discovery approach based on chemical biology

Why is probe-based drug discovery the key to leveraging innovation?

Oncodesign has developed a unique approach to drug discovery using probes which is highly complementary to the more traditional target-based approach. We have shown that this approach can generate exceptional drug candidates. It thus brings new hope to patients with cancer, inflammatory and autoimmune diseases as well as central nervous system diseases.

Our process is based on the diversified chemistry of Nanocyclix®, which provides high-quality probes, i.e. potent macrocyclic kinase inhibitors with initial selectivity against a small “signature subset” of kinases.

Discover our partnerships

Nanocyclix® Probes Criteria
Attractive PhysChem Properties: MW < 400, 2 < clogp < 4, LE > 0.3, TPSA < 120A
Potent in binding/biochemistry assays: Kd/IC50 < 50nM
Selective against kinome: S50 @0.1µM < 5% / @1µM < 10%
Kinase signature identified
Identified therapeutic indication
In vitro target engagement or functional activity demonstrated
eADME characteristics demonstrating drug-like potential
Preliminary SAR demonstrated with minimal number of molecules
Attractive PhysChem Properties: MW<400, 20.3, TPSA<120A

 

 

chimie_selective-2-EN

Nanocyclix® Probe-based approach

Extensive profiling of the human kinome and early ADME testing  can identify probes of interest with initial potency and selectivity against a small number of kinases. For selected inhibitor/target pairs, extensive literature and patent research is performed during the probe qualification phase to establish hypotheses on their therapeutic benefit. In the next step of probe orientation, Nanocyclix® probes are used to validate these hypotheses in both mechanism-based and translational target engagement models.

Probe to lead and lead optimization rely on the intrinsic properties of Nanocyclix® inhibitors; we improve the parameters of the molecules to a predefined Targeted Profile Product (TPP) while maintaining initial potency and selectivity to select a preclinical candidate. The molecules undergo an exhaustive series of biological tests, while at the same time continuing their optimization cycles in medicinal chemistry.

During these early steps, molecules and programs are already available for co-development partnerships.

See Nanocyclix® in details

A diverse set of approximately 500 Nanocyclix®

We also selected a diverse set of approximately 500 Nanocyclix® molecules from different chemical series. This set of inhibitors based on the human kinome is a unique asset for phenotype-based approaches, as it ensures potency, selectivity, cellular activity and novelty from the outset. The deconvolution of active hits is supported by our broad knowledge base and is initially entirely focused on kinome activity.

Talk with an expert

biologie-chimique-tumor-cell-line
biologie-chimique-cancer-patients-derived-organoids